about
Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromesSafety evaluation of tirofiban.Eptifibatide: The evidence for its role in the management of acute coronary syndromes.Abciximab as an adjunctive therapy for patients undergoing percutaneous coronary interventions.Humanized mouse model of thrombosis is predictive of the clinical efficacy of antiplatelet agents.Integrin targeted therapeutics.Humanizing thrombi in mice.Advances in revascularization for acute ischemic stroke treatment.Inhibition of platelet function by abciximab or high-dose tirofiban in patients with STEMI undergoing primary PCI: a randomised trial.Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins.How Safe is Eptifibatide during Urgent Carotid Artery Stenting?Current strategies with high-dose tirofiban.Present and evolving role of eptifibatide in the treatment of acute coronary syndromes.Elevating local concentrations of GPIIb-IIIa antagonists counteracts platelet thrombus stability.Glycoprotein IIb/IIIa receptor inhibitors in 2008: do they still have a role?Chemical structures and mode of action of intravenous glycoprotein IIb/IIIa receptor blockers: A review.Advances in revascularization for acute ischemic stroke treatment: an update.A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?Glycoprotein IIb-IIIa inhibitors.Review of Currently Available GP IIb/IIIa Inhibitors and Their Role in Peripheral Vascular Interventions.Antiplatelet medications and evolving antithrombotic medication.Platelet-targeted pharmacologic treatments as anti-cancer therapy.Abciximab: a reappraisal of its use in coronary care.Tirofiban: a critical reappraisal of the clinical use, recent developments and future perspectives.Boosting platelet inhibition in poor responder to aspirin and clopidogrel undergoing percutaneous coronary intervention: role of tirofiban.Integrins as Therapeutic Targets: Successes and Cancers.Eptifibatide is associated with significant cost savings and similar clinical outcomes to abciximab when used during primary percutaneous coronary intervention for ST-elevation myocardial infarction: An observational cohort study of 3863 patients.Platelet aggregation pathway.RGD-ligand mimetic antagonists of integrin alphaIIbbeta3 paradoxically enhance GPVI-induced human platelet activation.Platelet Integrins in Tumor Metastasis: Do They Represent a Therapeutic Target?Advanced assessment of platelet function during adult donor care.A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.Intracoronary bolus-only compared with intravenous bolus plus infusion of tirofiban application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.Predictors of high on-clopidogrel platelet reactivity in patients with acute coronary syndrome.A Case of Hyperacute Severe Thrombocytopenia Occurring Less than 24 Hours after Intravenous Tirofiban Infusion.Novel aspects of antiplatelet therapy in cardiovascular disease
P2860
Q28199725-1E7B39DE-A720-4E59-A96D-8DC2329B1335Q33391065-A826FB6C-C8A2-4B0F-B0C3-6A9591EB21D7Q33391279-E6EB993D-C86F-4237-B326-2DDE62CAFA52Q33393501-C91279E6-9A86-41F5-B5B2-38BA4DDD8B03Q33789829-7A71716E-F9A8-424C-888F-A166702DFDF7Q34912684-8D02655C-DFD0-4C88-8198-1F63D81FE971Q35109254-53BA7685-8C19-4E30-92E3-19145B908CA6Q36106802-7F4653F9-DD54-43FF-83DD-6C2A108060B8Q36151450-B883455C-4417-4DA5-AE8A-D4AF97BAA1DDQ36269613-2AB643CD-8530-40A3-A580-6BF382189F4DQ36602197-288BA6CA-0C7A-452E-AE92-B0714A1751CCQ36788433-67296979-3ABA-418E-8C34-230F267B0781Q36815950-5FF8DED2-27A9-479B-9234-D8396041223FQ36927583-1179BF07-29D3-40BF-8D75-13416CA076C5Q37126729-9B8ACA52-84F5-4265-8CBB-BFB3756C6A39Q37431543-0378F034-5AB7-45DF-9CF2-6E3CE02F2D71Q37907291-9547A07C-90F9-4DA2-BEEE-4E7A9C2CF86FQ37908891-77737781-70B8-4FC5-B537-6DD31BB085DFQ37942701-815B7839-7BBA-4B93-81DB-8CD758A67CE8Q38006947-AFF779F2-D600-4047-8EE0-70D4E5983913Q38075455-A5F4414A-0714-4C7F-88AD-F44672ECB5A3Q38657846-07DCB33C-3A18-4352-A875-B562C16CA45BQ40119259-B95C16B5-E5ED-4AD7-92CF-D26816ADABF2Q40361591-C141BB67-0EAD-46B2-B9C0-2E417F8D92ACQ40539804-AD7B21E2-A4F2-42A4-AA7B-9F94EA58E2E1Q41670949-8A03BD1A-80B2-405E-97D9-8AA3F6D1342BQ42375573-CE5522F8-81B6-43A0-8911-5B33F545C420Q42796609-1EF5F7E7-8336-4F58-98B3-0E6F39DA1CF4Q43225359-47086639-3CF7-4EAE-B6EF-4D958BB18D4FQ44522050-8CECE309-55C4-4E1E-B25D-D6A2AB377EF4Q48858813-54B0CFFB-E394-4D76-84D1-B62977FED2C6Q51690540-23631060-F308-46E3-9024-ABF481E09550Q53228498-81860046-1BE1-462E-87B8-A0DA0F958804Q53393756-25179387-D8BD-426F-AD47-9B7B9B91B50BQ55442994-F917F4A8-93D2-43D9-A325-C47542C8D719Q57179203-CB96912D-CEE3-45EA-94A9-FF1C629B1AC6
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Comparative pharmacology of GP IIb/IIIa antagonists
@ast
Comparative pharmacology of GP IIb/IIIa antagonists
@en
Comparative pharmacology of GP IIb/IIIa antagonists
@nl
type
label
Comparative pharmacology of GP IIb/IIIa antagonists
@ast
Comparative pharmacology of GP IIb/IIIa antagonists
@en
Comparative pharmacology of GP IIb/IIIa antagonists
@nl
prefLabel
Comparative pharmacology of GP IIb/IIIa antagonists
@ast
Comparative pharmacology of GP IIb/IIIa antagonists
@en
Comparative pharmacology of GP IIb/IIIa antagonists
@nl
P1476
Comparative pharmacology of GP IIb/IIIa antagonists
@en
P2093
Artur-Aron Weber
Karsten Schrör
P356
10.1023/B:THRO.0000003308.63022.8D
P407
P577
2003-04-01T00:00:00Z
P6179
1036709376